Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid beta Antibody in Patients With Alzheimer's Disease.
Phase of Trial: Phase III
Latest Information Update: 18 May 2017
At a glance
- Drugs Solanezumab (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Registrational
- Acronyms EXPEDITION-EXT
- Sponsors Eli Lilly
- 07 Jun 2017 Biomarkers information updated
- 29 Mar 2017 This trial has been completed in Spain (End date:2017-02-17) as per European Clinical Trials Database record.
- 07 Mar 2017 Status changed from active, no longer recruiting to discontinued.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History